{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:06:50Z","timestamp":1792822010418,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00198-021-06291-w","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T02:02:40Z","timestamp":1642212160000},"page":"1155-1164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study"],"prefix":"10.1007","volume":"33","author":[{"given":"E. C.-C.","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.-C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. L.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-W.","family":"Sing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.-L.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-C.","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4623-5561","authenticated-orcid":false,"given":"Y.-H. Kao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"6291_CR1","doi-asserted-by":"publisher","unstructured":"Hernlund E, Svedbom A, Iverg\u00e5rd M, et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. https:\/\/doi.org\/10.1007\/s11657-013-0136-1","DOI":"10.1007\/s11657-013-0136-1"},{"key":"6291_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11657-018-0549-y","volume":"14","author":"F Yu","year":"2019","unstructured":"Yu F, Xia W (2019) The epidemiology of osteoporosis, associated fragility fractures, and management gap in China. Arch Osteoporos 14:32. https:\/\/doi.org\/10.1007\/s11657-018-0549-y","journal-title":"Arch Osteoporos"},{"key":"6291_CR3","unstructured":"International Osteoporosis Foundation. The Asia-Pacific Regional Audit. Epidemiology, Costs & Burden of Osteoporosis in 2013. https:\/\/www.osteoporosis.foundation\/sites\/iofbonehealth\/files\/2019-06\/2013_Asia_Pacific_Audit_English.pdf. Accessed 29 Jan 2021"},{"issue":"Suppl 2","key":"6291_CR4","first-page":"1","volume":"19","author":"T-P Ip","year":"2013","unstructured":"Ip T-P, Cheung S-KW et al (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(Suppl 2):1\u201340","journal-title":"Hong Kong Med J"},{"key":"6291_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733. https:\/\/doi.org\/10.1007\/s00198-006-0172-4","journal-title":"Osteoporos Int"},{"key":"6291_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jama.2009.50","volume":"301","author":"D Bliuc","year":"2009","unstructured":"Bliuc D, Nguyen ND, Milch VE et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513\u2013521. https:\/\/doi.org\/10.1001\/jama.2009.50","journal-title":"JAMA"},{"key":"6291_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.afos.2018.03.003","volume":"4","author":"C-L Cheung","year":"2018","unstructured":"Cheung C-L, Ang SB, Chadha M et al (2018) An updated hip fracture projection in Asia: The Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia 4:16\u201321. https:\/\/doi.org\/10.1016\/j.afos.2018.03.003","journal-title":"Osteoporos Sarcopenia"},{"key":"6291_CR8","unstructured":"U.S. Food and Drug Administration (2020) Enhancing the Diversity of Clinical Trial Populations \u2014 Eligibility Criteria, Enrollment Practices, and Trial Designs: Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enhancing-diversity-clinical-trial-populations-eligibility-criteria-enrollment-practices-and-trial. Accessed 5 Jan 2021"},{"key":"6291_CR9","unstructured":"U.S. Food and Drug Administration (2018) E17 General Principles for Planning and Design of Multiregional Clinical Trials: Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e17-general-principles-planning-and-design-multi-regional-clinical-trials. Accessed 5 Jan 2021"},{"key":"6291_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D et al (2015) A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 16:495. https:\/\/doi.org\/10.1186\/s13063-015-1023-4","journal-title":"Trials"},{"key":"6291_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156068","volume":"11","author":"K Barnard","year":"2016","unstructured":"Barnard K, Lakey WC, Batch BC et al (2016) Recent clinical trials in osteoporosis: a firm foundation or falling short? PLoS ONE 11:e0156068. https:\/\/doi.org\/10.1371\/journal.pone.0156068","journal-title":"PLoS ONE"},{"key":"6291_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11914-019-00551-9","volume":"17","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG, Danila MI (2019) Pragmatic clinical trials in osteoporosis. Curr Osteoporos Rep 17:521\u2013526. https:\/\/doi.org\/10.1007\/s11914-019-00551-9","journal-title":"Curr Osteoporos Rep"},{"key":"6291_CR13","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ et al (2016) Real-world evidence - What is it and what can it tell us? N Engl J Med 375:2293\u20132297. https:\/\/doi.org\/10.1056\/NEJMsb1609216","journal-title":"N Engl J Med"},{"key":"6291_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"6291_CR15","unstructured":"Duke-Margolis Center for Health Policy (2017) A framework for regulatory use of real-world evidence [Internet]. https:\/\/healthpolicy.duke.edu\/publications\/framework-regulatory-use-real-world-evidence. Accessed 30 Jan 2018"},{"key":"6291_CR16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","volume":"11","author":"C-Y Hsieh","year":"2019","unstructured":"Hsieh C-Y, Su C-C, Shao S-C et al (2019) Taiwan\u2019s National Health Insurance Research Database: past and future. Clin Epidemiol 11:349\u2013358. https:\/\/doi.org\/10.2147\/CLEP.S196293","journal-title":"Clin Epidemiol"},{"key":"6291_CR17","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/pds.4208","volume":"26","author":"C-W Sing","year":"2017","unstructured":"Sing C-W, Woo Y-C, Lee ACH et al (2017) Validity of major osteoporotic fracture diagnosis codes in the Clinical Data Analysis and Reporting System in Hong Kong. Pharmacoepidemiol Drug Saf 26:973\u2013976. https:\/\/doi.org\/10.1002\/pds.4208","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6291_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","volume":"28","author":"S-C Shao","year":"2019","unstructured":"Shao S-C, Chan Y-Y, Kao Yang Y-H et al (2019) The Chang Gung Research Database-a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf 28:593\u2013600. https:\/\/doi.org\/10.1002\/pds.4713","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6291_CR19","unstructured":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan (2018) Survey Results of Chinese Smoking Behavior. https:\/\/www.hpa.gov.tw\/Pages\/Detail.aspx?nodeid=1718&pid=9913. Accessed 1 Aug 2020"},{"key":"6291_CR20","unstructured":"Parsons LS (2001) Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference, Long Beach, CA. https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi26\/p214-26.pdf. Accessed 22 Apr 2019"},{"key":"6291_CR21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss S, Rassen JA, Glynn RJ et al (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20:512\u2013522. https:\/\/doi.org\/10.1097\/EDE.0b013e3181a663cc","journal-title":"Epidemiology"},{"key":"6291_CR22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","volume":"15","author":"S Schneeweiss","year":"2006","unstructured":"Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15:291\u2013303. https:\/\/doi.org\/10.1002\/pds.1200","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6291_CR23","unstructured":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine Brigham and Women\u2019s Hospital Harvard Medical School. Sensitivity Analysis. https:\/\/www.drugepi.org\/company\/software#Sensitivity. Accessed 7 Mar 2019"},{"key":"6291_CR24","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.2337\/dc19-0069","volume":"42","author":"E Patorno","year":"2019","unstructured":"Patorno E, Schneeweiss S, Gopalakrishnan C et al (2019) Using real-world data to predict findings of an ongoing phase iv cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride. Diabetes Care 42:2204\u20132210. https:\/\/doi.org\/10.2337\/dc19-0069","journal-title":"Diabetes Care"},{"key":"6291_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pds.4295","volume":"26","author":"SV Wang","year":"2017","unstructured":"Wang SV, Schneeweiss S, Berger ML et al (2017) Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0. Pharmacoepidemiol Drug Saf 26:1018\u20131032. https:\/\/doi.org\/10.1002\/pds.4295","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6291_CR26","doi-asserted-by":"publisher","unstructured":"Nosek BA, Errington TM (2017) Making sense of replications. Elife 6:e23383. https:\/\/doi.org\/10.7554\/eLife.23383","DOI":"10.7554\/eLife.23383"},{"key":"6291_CR27","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00198-012-1984-z","volume":"24","author":"Y-K Soong","year":"2013","unstructured":"Soong Y-K, Tsai K-S, Huang H-Y et al (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24:511\u2013521. https:\/\/doi.org\/10.1007\/s00198-012-1984-z","journal-title":"Osteoporos Int"},{"key":"6291_CR28","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.4065\/81.8.1013","volume":"81","author":"ES Siris","year":"2006","unstructured":"Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013\u20131022. https:\/\/doi.org\/10.4065\/81.8.1013","journal-title":"Mayo Clin Proc"},{"key":"6291_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/clpt.2011.62","volume":"90","author":"T-C Lin","year":"2011","unstructured":"Lin T-C, Yang C-Y, Yang Y-HK, Lin S-J (2011) Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther 90:109\u2013116. https:\/\/doi.org\/10.1038\/clpt.2011.62","journal-title":"Clin Pharmacol Ther"},{"key":"6291_CR30","doi-asserted-by":"publisher","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","volume":"25","author":"M Di Maio","year":"2020","unstructured":"Di Maio M, Perrone F, Conte P (2020) Real-world evidence in oncology: opportunities and limitations. Oncologist 25:e746\u2013e752. https:\/\/doi.org\/10.1634\/theoncologist.2019-0647","journal-title":"Oncologist"},{"key":"6291_CR31","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11:437\u2013441. https:\/\/doi.org\/10.1038\/nrrheum.2015.30","journal-title":"Nat Rev Rheumatol"},{"key":"6291_CR32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/joim.13354","volume":"290","author":"S-H Fu","year":"2021","unstructured":"Fu S-H, Wang C-Y, Hung C-C et al (2021) Increased fracture risk after discontinuation of anti-osteoporosis medications among hip fracture patients: A population-based cohort study. J Intern Med 290:1194\u20131205. https:\/\/doi.org\/10.1111\/joim.13354","journal-title":"J Intern Med"},{"key":"6291_CR33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059\u20131066. https:\/\/doi.org\/10.1359\/JBMR.040305","journal-title":"J Bone Miner Res"},{"key":"6291_CR34","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporosis Int 28:2701\u20132705. https:\/\/doi.org\/10.1007\/s00198-017-4080-6","journal-title":"Osteoporosis Int"},{"key":"6291_CR35","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B et al (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31:2093\u20132102. https:\/\/doi.org\/10.1007\/s00198-020-05507-9","journal-title":"Osteoporos Int"},{"key":"6291_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"6291_CR37","unstructured":"World Health Organization (2018) Ageing and Health. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/ageing-and-health. Accessed 29 Jan 2021"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06291-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-06291-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-06291-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T13:04:45Z","timestamp":1649941485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-06291-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6291"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-06291-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"10 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study protocol was approved by the National Cheng Kung University Institutional Review Board (HREC#107\u2013008) in Taiwan and the Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster (UW 19\u2013154) in Hong Kong.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ECCL has received honoraria from AbbVie, grant funding from Amgen, AbbVie and Takeda, and financial support from Taiwan\u2019s Ministry of Science and Technology; TCL, JLL, and LC are employees and stockholders of Amgen; ICKW has received grant support from Amgen; YHKY has received grant support from Amgen; CWS, CLC, and SCS have no conflicts to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}